NASDAQ:NTGN - Neon Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.59 -0.49 (-9.65 %) (As of 05/22/2019 04:00 PM ET)Previous Close$5.08Today's Range$4.50 - $5.1352-Week Range$4.20 - $16.23Volume131,051 shsAverage Volume142,526 shsMarket Capitalization$130.04 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. Receive NTGN News and Ratings via Email Sign-up to receive the latest news and ratings for NTGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTGN Previous Symbol CUSIPN/A CIKN/A Webhttp://www.neontherapeutics.com/ Phone617-337-4701Debt Debt-to-Equity Ratio0.09 Current Ratio7.30 Quick Ratio8.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.90 per share Price / Book1.58Profitability EPS (Most Recent Fiscal Year)($5.54) Net Income$-76,930,000.00 Net MarginsN/A Return on Equity-73.13% Return on Assets-65.66%Miscellaneous Employees102 Outstanding Shares28,331,000Market Cap$130.04 million Next Earnings Date8/5/2019 (Estimated) OptionableNot Optionable Neon Therapeutics (NASDAQ:NTGN) Frequently Asked Questions What is Neon Therapeutics' stock symbol? Neon Therapeutics trades on the NASDAQ under the ticker symbol "NTGN." How were Neon Therapeutics' earnings last quarter? Neon Therapeutics Inc (NASDAQ:NTGN) issued its quarterly earnings data on Monday, May, 13th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.73) by $0.03. View Neon Therapeutics' Earnings History. When is Neon Therapeutics' next earnings date? Neon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Neon Therapeutics. What price target have analysts set for NTGN? 4 brokers have issued 1-year target prices for Neon Therapeutics' shares. Their predictions range from $15.00 to $23.00. On average, they anticipate Neon Therapeutics' stock price to reach $19.20 in the next twelve months. This suggests a possible upside of 318.3% from the stock's current price. View Analyst Price Targets for Neon Therapeutics. What is the consensus analysts' recommendation for Neon Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neon Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neon Therapeutics. Has Neon Therapeutics been receiving favorable news coverage? News articles about NTGN stock have been trending negative on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Neon Therapeutics earned a daily sentiment score of -2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of Neon Therapeutics' key competitors? Some companies that are related to Neon Therapeutics include DBV TECHNOLOGIE/S (DBVT), Scholar Rock (SRRK), Acorda Therapeutics (ACOR), Mesoblast (MESO), Translate Bio (TBIO), Replimune Group (REPL), Krystal Biotech (KRYS), Avrobio (AVRO), Agenus (AGEN), Gritstone Oncology (GRTS), Adaptimmune Therapeutics (ADAP), PDL BioPharma (PDLI), LogicBio Therapeutics (LOGC), CASI Pharmaceuticals (CASI) and Cellular Biomedicine Group (CBMG). What other stocks do shareholders of Neon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neon Therapeutics investors own include Alibaba Group (BABA), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), Honeywell International (HON), Altria Group (MO), Home Depot (HD), Johnson & Johnson (JNJ), Mcdonald's (MCD) and Raytheon (RTN). Who are Neon Therapeutics' key executives? Neon Therapeutics' management team includes the folowing people: Mr. Hugh O'Dowd, Pres, CEO & Director (Age 54)Dr. Eric S. Lander, Founder & Director (Age 62)Dr. Yasir B. Al-Wakeel, Chief Financial Officer (Age 37)Dr. Richard Gaynor, Pres of R&D (Age 69)Dr. Edward Fritsch Ph.D., Founder and Chief Technology Officer When did Neon Therapeutics IPO? (NTGN) raised $101 million in an initial public offering on Wednesday, June 27th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities acted as the underwriters for the IPO and Oppenheimer was co-manager. Who are Neon Therapeutics' major shareholders? Neon Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (7.22%), Wellington Management Group LLP (5.56%), ArrowMark Colorado Holdings LLC (3.34%), BlackRock Inc. (2.42%), Northern Trust Corp (0.54%) and Jacobs Levy Equity Management Inc. (0.48%). View Institutional Ownership Trends for Neon Therapeutics. Which major investors are selling Neon Therapeutics stock? NTGN stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, FMR LLC, Parametric Portfolio Associates LLC and Morgan Stanley. View Insider Buying and Selling for Neon Therapeutics. Which major investors are buying Neon Therapeutics stock? NTGN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Oxford Asset Management LLP, Jacobs Levy Equity Management Inc., Northern Trust Corp, ArrowMark Colorado Holdings LLC, Acadian Asset Management LLC and Oppenheimer & Co. Inc.. View Insider Buying and Selling for Neon Therapeutics. How do I buy shares of Neon Therapeutics? Shares of NTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Neon Therapeutics' stock price today? One share of NTGN stock can currently be purchased for approximately $4.59. How big of a company is Neon Therapeutics? Neon Therapeutics has a market capitalization of $130.04 million. The company earns $-76,930,000.00 in net income (profit) each year or ($5.54) on an earnings per share basis. Neon Therapeutics employs 102 workers across the globe. What is Neon Therapeutics' official website? The official website for Neon Therapeutics is http://www.neontherapeutics.com/. How can I contact Neon Therapeutics? Neon Therapeutics' mailing address is 40 ERIE STREET SUITE 110, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4701 or via email at [email protected] MarketBeat Community Rating for Neon Therapeutics (NASDAQ NTGN)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 74 (Vote Outperform)Underperform Votes: 84 (Vote Underperform)Total Votes: 158MarketBeat's community ratings are surveys of what our community members think about Neon Therapeutics and other stocks. Vote "Outperform" if you believe NTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Marijuana Stocks Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.